JAZZ
Jazz Pharmaceuticals plc
+1.44 (+0.59%)245.03USD164K成交股數15.9B市值16.8本益比(近四季)3.5股價營收比+15.6%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.2B+35% | 1.1B-2% | 1.1B+7% | 1.0B+2% | 898M-0% | 1.1B+12% | 1.1B+10% | 1.0B+15% | 902M | 972M | 957M | 893M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 208M | 196M | 198M | 190M | 181M | 241M | 200M | 221M | 223M | 234M | 209M | 189M |
| 銷售管理費用 | 389M | 353M | 531M | 358M | 514M | 369M | 326M | 339M | 352M | 308M | 341M | 298M |
| 營業利益 | 248M-544% | 337M+76% | 57.5M-78% | −686M-444% | −55.9M-184% | 191M+11% | 260M+65% | 199M+58% | 66.2M | 172M | 158M | 126M |
| 營業利益率 | 20.5% | 31.5% | 5.1% | -65.6% | -6.2% | 17.5% | 24.7% | 19.5% | 7.3% | 17.7% | 16.5% | 14.1% |
| 稅後淨利 | 193M-308% | 293M+53% | 251M+17% | −719M-526% | −92.5M+533% | 191M+30% | 215M+106% | 169M+143% | −14.6M | 147M | 104M | 69.4M |
| 淨利率 | 16.0% | 27.4% | 22.3% | -68.7% | -10.3% | 17.6% | 20.4% | 16.5% | -1.6% | 15.1% | 10.9% | 7.8% |
| 稀釋 EPS | 2.78-283% | 4.43+49% | 4.08+19% | -11.74-571% | -1.52+561% | 2.97+39% | 3.42+125% | 2.49+139% | -0.23 | 2.14 | 1.52 | 1.04 |
| 稀釋股數 | 69.4M | 66.1M | 61.6M | 61.2M | 61.0M | 66.0M | 63.2M | 69.6M | 62.5M | 71.3M | 73.5M | 73.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 1.6B | 1.8B | 1.3B | 1.2B | 1.9B | 2.4B | 2.2B | 1.4B | 1.4B | 1.3B | 1.3B | 1.2B |
| 應收帳款 | 881M | 836M | 764M | 714M | 653M | 717M | 724M | 698M | 707M | 628M | 610M | 624M |
| 存貨 | 443M | 438M | 483M | 505M | 493M | 480M | 539M | 543M | 577M | 612M | 657M | 675M |
| 總資產 | 11.1B | 11.9B | 11.4B | 10.9B | 11.5B | 12.0B | 12.3B | 11.4B | 11.3B | 11.2B | 11.3B | 11.0B |
| 有息負債 | 3.3B | 4.3B | 4.3B | 4.3B | 5.3B | 6.1B | 6.1B | 5.1B | 5.1B | 5.1B | 5.7B | 5.7B |
| 總負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 股東權益 | 4.8B | 4.5B | 4.0B | 3.7B | 4.2B | 4.1B | 4.2B | 3.8B | 3.7B | 3.5B | 3.5B | 3.3B |
| 負債比 | – | – | – | – | – | – | – | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | −1.7B | −2.5B | −3.0B | −3.1B | −3.5B | −3.7B | −3.9B | −3.7B | −3.7B | −3.8B | −4.4B | −4.5B |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 408M | – | – | 430M+61% | – | – | – | 267M | – | – | 321M |
| 資本支出 | – | 19.7M | – | – | 13.9M | – | – | – | 6.9M | – | – | 3.8M |
| 自由現金流 | – | 389M | – | – | 416M+60% | – | – | – | 260M | – | – | 317M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 36.3% | – | – | 46.3% | – | – | – | 28.9% | – | – | 35.5% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
地區2025 年度 · 4.3B
| 美國 | 3.8B | 89.8% | +4.7% |
|---|---|---|---|
| 歐洲 | 341M | 8.0% | +9.1% |
| 其他國家 | 94.9M | 2.2% | -1.3% |
產品／服務2025 年度 · 1.4B
| Epidiolex Epidyolex | 1.1B | 78.3% | +8.9% |
|---|---|---|---|
| Vyxeos | 147M | 10.9% | -9.8% |
| Xyrem | 146M | 10.8% | -37.5% |
| Product And Services Product Sales Net Of Deductions 小計 | 4.0B | 297.5% | +5.3% |
| Total Neuroscience 小計 | 2.9B | 212.9% | +6.7% |
| Xywav 小計 | 1.7B | 122.6% | +12.5% |
| Total Oncology 小計 | 1.1B | 83.5% | +1.6% |
| Rylaze Enrylaze 小計 | 403M | 29.8% | -1.9% |
| Zepzelca 小計 | 307M | 22.7% | -4.1% |
| Product And Services Royalties And Contract Revenue 小計 | 246M | 18.2% | -0.8% |
| High Sodium AG Oxybate Product Royalty Revenue 小計 | 212M | 15.7% | -2.7% |
| Defitelio Defibrotide 小計 | 199M | 14.7% | -7.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 4.3B | +4.9% | −356M | -8.3% | -5.84 | 1.3B |
| FY2024 | 4.1B | +6.1% | 560M | 13.8% | 8.65 | 1.4B |
| FY2023 | 3.8B | +4.8% | 415M | 10.8% | 6.10 | 1.1B |
| FY2022 | 3.7B | +18.3% | −224M | -6.1% | -3.58 | 1.2B |
| FY2021 | 3.1B | +30.9% | −330M | -10.7% | -5.52 | 751M |
| FY2020 | 2.4B | +9.3% | 239M | 10.1% | 4.22 | 885M |
| FY2019 | 2.2B | +14.3% | 523M | 24.2% | 9.09 | 736M |
| FY2018 | 1.9B | – | 447M | 23.6% | 7.30 | 779M |